News
,Press Releases
Biocytogen Officially Launches RenMice® Series
Fully Human Antibody and TCR Mouse Models Showcase Biocytogen’s Capabilities to Innovate the Discovery of Novel Biologic Drugs Beijing, China, September 15, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) officially announces the RenMice® series, which includes a collection of…
Keep ReadingNews
,Press Releases
Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development
Beijing, China, September 7, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody evaluation, option and license agreement with Myricx Bio (‘Myricx’), a UK…
Keep ReadingNews
,Press Releases
Biocytogen Establishes Two Business Divisions to Distinguish Preclinical Models and Services (BioMice) From Antibody Drug R&D
Beijing, China, August 31, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to represent the company’s product, service, and asset portfolio. Over the last decade, Biocytogen has developed several…
Keep ReadingNews
,Press Releases
Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies
BEIJING, China, August 30, 2023 – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), announced today that the company has entered into a technology transfer agreement with Syncromune, Inc. (“Syncromune”), a US-based clinical-stage…
Keep ReadingNews
,Press Releases
Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth
BEIJING, China–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth. Project Integrum is a large-scale R&D project…
Keep ReadingNews
The Key Technology Of Biocytogen’s Fully Human Antibody Renmab Platform Has Been Granted A Chinese Patent
Beijing, China, July 11, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced its independently developed key technology of RenMabTM platform has been granted a Chinese patent. The patent is related to the key technology of Biocytogen’s fully human antibody…
Keep ReadingNews
,Press Releases
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
Exclusive License Agreement for an Oncological Target Antibody to Develop Best-In-Class ADC Beijing, China and London, UK, July 5, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody…
Keep ReadingNews
,Press Releases
Biocytogen Announces RenLite® Licensing Agreement with Janssen
BEIJING, March 8, 2023 — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Jonson & Johnson (“Janssen”). Under the agreement, Biocytogen…
Keep ReadingNews
,Press Releases
Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008
BEIJING, China, February 27, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a…
Keep ReadingNews
,Press Releases
Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
BEIJING, China, February 21, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen’s proprietary fully…
Keep Reading